TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pulmonary artery hypertension (group 1 of the Nice classification of pulmonary hypertension)~  * Aged over 18 years old~ * NYHA class III or IV~ * Not controlled by optimal medical management as defined by:~    * dual therapy including a prostacyclin.~   * or dual therapy including an endothelin receptor antagonist and a~ * 5-phosphodiesterase inhibitors, in patients with contra-indication of prostacyclin, poor tolerance to this treatment, prostacyclin derivative treatment failure or patient refusal.~ * Valid status in the social security system~ * Signed informed consent~Exclusion Criteria:~* Patient eligible for pulmonary transplantation~* Pregnancy or breastfeeding~* Adults of the age of majority subject to guardianship court order or deprived of liberty~* Patient with history of radio frequency procedure~* Known heparin allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denervation (Type: EXPERIMENTAL): None
- control group (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cystic fibrosis (CF) and homozygous for F508del-CFTR mutation~* Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height~* Willing to use at least 2 highly effective birth control methods during the study~* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator~* Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study~* History of alcohol, medication or illicit drug abuse within one year prior to Day 1~* Abnormal liver function \>=3 x the upper limit of normal~* Abnormal renal function at Screening~* History of solid organ or hematological transplantation~* Pregnant or breast-feeding (for women)~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to screening~* Previous participation in a VX-809 study~* Used inhaled hypertonic saline treatment~* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
- Ivacaftor (Type: EXPERIMENTAL): Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent~2. Women of child-bearing potential must have a negative pregnancy test~Multiple Myeloma:~Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with at least two prior lines of therapy.~Lymphoma:~Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received.~Exclusion Criteria:~1. Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464:~   1. Major surgery within 28 days~  2. Radiation/chemotherapy within 21 days~  3. Monoclonal antibodies within 28 days~  4. Corticosteroid administration \>20 mg/day of prednisone or equivalent within 14 days~  5. Proteasome inhibitors within 14 days~  6. Immunomodulatory agents within 7 days~  7. Stem cell transplant within 3 months~  8. Current immunosuppressive treatment for graft versus host disease~  9. Current use of an investigational agent~2. Active graft versus host disease~3. Known serious illness or medical condition~4. Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class~5. Pregnant or breast-feeding female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS4464 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label~3. Patient willing and able to complete the questionnaires~Exclusion Criteria:~1. Patients treated outside of the approved Swiss label for Siponimod~2. Prior treatment or already ongoing treatment with Siponimod~3. Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer~4. Subjects who are not able to provide consent due to incapable judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siponimod (Type: None): Patients administered Siponimod as per Swiss label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effect on Quality of Recovery Outcome Between Systemic Lidocaine and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II patients aged between 20 and 65 year undergoing laparoscopic cholecystectomy due to gallbladder polyp or asymptomatic gallstones without cholecystitis~Exclusion Criteria:~1. Steroid therapy or immunocompromised patients~2. Diabetes mellitus~3. Allergy to lidocaine or dexamethasone~4. Severe renal dysfunction (serum creatinine more than 1.6mg/dl)~5. Severe liver disease ( liver enzymes more than two times normal values)~6. History of atrioventricular block~7. Have a difficulty in understanding QoR-40 (40-item quality-of-recovery scoring system) or Korean language~8. History of physicologic disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine group (Type: EXPERIMENTAL): None
- Dexamethasone group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Agents for Treatment of High-risk COVID-19 Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Age ≥18 years~* Laboratory-confirmed SARS-CoV-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of COVID-19 disease~* Patients must have adequate organ and marrow function measured within the last 6 months~* Subjects must have at least one of the following high-risk features for clinical deterioration:~  * Hypertension~ * Diabetes Mellitus~ * Moderate to severe Chronic Obstructive Pulmonary Disease, Emphysema, Cystic Fibrosis, or Asthma~ * Cancer patients who have received any immunosuppressive drugs within a year from enrollment~ * Sickle Cell disease or thalessemia~ * Age \> or = 50~ * BMI \> or = 30~ * Living in a nursing home or long-term facility~ * Underlying serious heart condition as determined by the treating physician~ * Immunocompromised subject as defined by the treating physician or COVID-19 Telehealth Treatment Team~Exclusion Criteria~* Severe or life threating COVID~* Weight less than 45 kg.~* Pregnant or breast-feeding females~* Subjects on dialysis or with creatinine clearance \< 45 ml/min~* Existing DMID Toxicity Scale for Determining Severity of Adverse Events grade 3 or greater hepatic failure~* Previously documented moderate or severe retinopathy or macular degeneration~* Uncontrolled Seizure disorder~* Prolonged QT, defined as QTc ≥470 milliseconds for men and as QTc ≥480 for women using Bazett's formula~* Known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial.~* Currently receiving any study medications for other indications~* Concurrent use of medication that would cause drug-drug interactions~* Patients with psychiatric illness/social situations that would limit compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm C: Ivermectin (Type: EXPERIMENTAL): Ivermectin
- Arm D: Camostat Mesilate (Type: EXPERIMENTAL): Camostat Mesilate
- Arm E: Artemesia annua (Type: EXPERIMENTAL): Artemesia annua tea or coffee
- Arm F: Artesunate (Type: EXPERIMENTAL): Artesunate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra-arterial Magnesium Administration for Acute Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with acute cerebral ischemia due to ICA or MCA occlusion,~2. Patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care.~3. Age 21-95.~Exclusion Criteria:~1. Severe renal impairment with creatinine 3.0 or higher,~2. Myasthenia gravis,~3. Second or third degree heart block without a pacemaker in place,~4. Technical inability to navigate microcatheter to target clot,~5. Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Regional Intra-arterial Magnesium 0.75g (Type: EXPERIMENTAL): Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
- Regional Intra-arterial magnesium 1.5g (Type: EXPERIMENTAL): Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
- Regional/ Distal (75/25%) Magnesium 1.5g (Type: EXPERIMENTAL): Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
- Regional/ Distal (50/50%) Magnesium 1.5g (Type: EXPERIMENTAL): Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced histologically confirmed well differentiated pancreatic neuroendocrine tumor~* Progressive disease within the last 12 months~* Measurable disease per RECIST Version 1.0 determined by multiphase MRI or triphasic CT~Exclusion Criteria:~* Prior treatment with mTOR or PI3K inhibitors~* Patients with more than 2 prior systemic treatment regimens~* Previous cytotoxic chemotherapy, targeted therapy, or biotherapy within the last 4 weeks~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BEZ235 (Type: EXPERIMENTAL): Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
- Everolimus (Type: ACTIVE_COMPARATOR): Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post-operative Pneumonia (POPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with lung lesions undergoing anatomic resection (lobectomy/segmentectomy/bilobectomy/pulmonary sleeve resection/pneumonectomy)~2. Patients with poor lung function (FEV1% \<50% or DLCO\<50% predicted or home oxygen requirement) and lung lesions undergoing non-anatomic lung resection (i.e. wedge resection).~3. Patients undergoing esophageal resection.~Exclusion Criteria:~1. Patients with ongoing symptomatic dental infections.~2. Patients with recent/ongoing pneumonia (\<15 days from initial surgical patient evaluation).~3. Patients who've received a therapeutic course of antibiotics within 15 days prior to thoracic surgery.~4. Patients with a preexisting tracheostomy.~5. Age\<18~6. Patients with an allergy to Peridex/chlorhexidine solution

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-operative brushing (Pilot Portion) (Type: EXPERIMENTAL): -Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
- Pre-operative & Post-Operative Brushing (Esophageal Resection) (Type: EXPERIMENTAL): * Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~* The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group.
- Pre-operative & Post-Operative Brushing (Lung Resection) (Type: EXPERIMENTAL): * Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~* The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary tumor or metastatic cancer with radiological diagnosis of spine metastasis~* The patient must have localized spine metastasis from the C1 to L5 levels by a screening imaging study~* Zubrod Performance Status 0-2~* History/physical examination within 2 weeks prior to registration~* Negative pregnancy test within 2 weeks prior to registration for women of childbearing potential~* Women of childbearing potential and male participants who are sexually active must agree to use a medically effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.~* MRI of the involved spine within 4 weeks prior to registration to determine the extent of the spine involvement~* Numerical Rating Pain Scale within 1 week prior to registration; the patient must have a score on the Scale of \>5 for at least one of the planned sites for spine radiosurgery. Patients taking medication for pain at the time of registration are eligible.~* Neurological examination within 1 week prior to registration to rule out rapid neurologic decline~Exclusion Criteria:~* Histology of myeloma, lymphoma or germ cell tumors.~* Non-ambulatory patients~* Spine instability due to a compression fracture~* \> 50% loss of vertebral body height~* Frank spinal cord displacement or epidural involvement with\> 25% encirclement of cord or \>25% spinal canal involvement.~* Prior radiation to the index spine~* Patients for whom an MRI of the spine is medically contraindicated~* Uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiosurgery/SBRT (Type: ACTIVE_COMPARATOR): Radiosurgery/SBRT
- External Beam Radiation Therapy (Type: ACTIVE_COMPARATOR): External Beam Radiation Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe UC defined by an overall Mayo score ≥ 5 and an endoscopic sub-score ≥ 2 points and rectal bleeding score ≥ 1 point~* Extension \> 15 cm from the anal margin~* Requiring treatment with biotherapy and meeting the indications for the treatment~* Affiliated with a social security scheme~Exclusion Criteria:~* Crohn's disease or unclassified colitis~* Severe acute colitis~* Requirement for immediate surgical treatment~* Previous treatment with vedolizumab or anti-TNF-α~* Contraindication to the use of vedolizumab or an anti-TNF-α agent~* Contraindication to the use of adalimumab~* Corticosteroid therapy \> 20 mg/day~* Corticosteroid therapy started within the previous two weeks~* Conventional Immunosppressor started within the previous month~* Colonic dysplasia or known cancer~* Likelihood to refuse two rectosigmoidoscopies, performed eighteen weeks apart~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VEDOLIZUMAB (Type: EXPERIMENTAL): 300 mg IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adults presenting for routine thyroid biopsy, paracentesis or thoracentesis in interventional radiology~Exclusion Criteria:~* Patients requiring sedation~* Patients with altered mental status~* Children~* Patients allergic to lidocaine or sodium bicarbonate

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): 10 mg/mL lidocaine; Frequency: 1
- Arm B (Type: ACTIVE_COMPARATOR): 9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
- Arm C (Type: ACTIVE_COMPARATOR): 7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
- Arm D (Type: ACTIVE_COMPARATOR): 5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Propofol Versus Volatile Anesthesia in Post Operative Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will undergo a stripping operation for varicose veins~* Surgery will be performed by one physician only~* Written informed consent~Exclusion Criteria:~* Any contraindications to the proposed interventions~* Procedures done under regional anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patients will receive propofol anesthesia during varicose vein stripping surgery.
- 2 (Type: ACTIVE_COMPARATOR): Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues